Testosterone Cypionate and Insulin Sensitivity: How Androgens Influence Blood Sugar Control

The connection between testosterone and metabolic health has been one of the most productive areas of endocrine research over the past two decades. Men with low testosterone are significantly more likely to develop insulin resistance, metabolic syndrome, and type 2 diabetes. Men who restore their testosterone levels consistently show improvements in fasting glucose, insulin sensitivity markers, and visceral fat distribution. Yet the relationship is not a simple “more testosterone equals better insulin sensitivity.” Supraphysiological doses introduce a different set of metabolic dynamics that most guides either ignore or get wrong. At Hemi Pharma UK, we want to lay out what the clinical evidence actually demonstrates, where the dose-response curve bends, and what this means for men using testosterone cypionate at both TRT and performance doses.

Key Takeaways

  • Clinically low testosterone is an independent risk factor for insulin resistance and metabolic syndrome. Restoring testosterone to the physiological range with testosterone cypionate reliably improves insulin sensitivity, reduces fasting glucose, and lowers HbA1c in hypogonadal men.
  • The primary mechanism linking testosterone to insulin sensitivity is its effect on body composition. Testosterone shifts the muscle-to-fat ratio in favour of lean tissue, which is the body’s largest glucose disposal organ, while reducing visceral adipose tissue, which is the body’s largest source of inflammatory insulin resistance signalling.
  • At supraphysiological doses, testosterone cypionate continues to improve body composition but may introduce confounding metabolic effects including altered hepatic lipid metabolism, increased haematocrit affecting blood viscosity, and oestradiol-driven fluid shifts that complicate metabolic blood work interpretation.
  • Practical monitoring on cycle should include fasting glucose, fasting insulin or HOMA-IR, HbA1c, and a lipid panel alongside standard hormone and haematology markers.
  • Diet composition matters more on cycle than off. Higher protein intake, controlled carbohydrate timing around training, and adequate fibre intake amplify the insulin-sensitising effects of testosterone cypionate, while caloric excess with high refined carbohydrate intake can partially negate them.

What Is Insulin Sensitivity and Why Does It Matter on Cycle?

Insulin sensitivity describes how effectively your cells respond to insulin’s signal to take up glucose from the bloodstream. High insulin sensitivity means a small amount of insulin moves a large amount of glucose into cells. Low insulin sensitivity, which is insulin resistance, means the pancreas must produce progressively more insulin to achieve the same glucose clearance. Over time, this escalation leads to beta-cell exhaustion, chronically elevated blood sugar, and eventually type 2 diabetes.

For men using testosterone cypionate, insulin sensitivity has direct implications for body composition outcomes. Insulin is an anabolic hormone. In an insulin-sensitive state, it preferentially shuttles nutrients into muscle tissue for glycogen replenishment and protein synthesis. In an insulin-resistant state, a larger proportion of circulating glucose and fatty acids are directed into adipose storage. This means that two men running identical testosterone cypionate doses with identical training programmes can get substantially different results based on their baseline insulin sensitivity and how they manage it through diet.

Understanding how testosterone cypionate interacts with insulin signalling is therefore not an academic exercise. It is a practical determinant of whether your cycle delivers lean tissue gains or a frustrating mix of muscle and fat. For a broader look at how testosterone cypionate influences body composition, see our guides on muscle growth and weight loss.

How Does Low Testosterone Cause Insulin Resistance?

The association between low testosterone and insulin resistance is one of the most replicated findings in male endocrinology. Dhindsa and colleagues published a landmark study demonstrating that hypogonadotropic hypogonadism occurs in approximately 33 percent of men with type 2 diabetes, a prevalence far higher than in the general male population (Dhindsa et al., J Clin Endocrinol Metab, 2004). This was not merely correlation. Subsequent mechanistic work established several causal pathways.

Visceral Adipose Tissue Accumulation

Testosterone is a primary regulator of fat distribution in men. When testosterone declines, visceral adipose tissue, the metabolically active fat that surrounds abdominal organs, preferentially expands. Visceral fat is not an inert energy store. It is an active endocrine organ that secretes pro-inflammatory adipokines including IL-6, TNF-α, and resistin, all of which directly impair insulin receptor signalling in muscle and liver tissue. The cycle is self-reinforcing: low testosterone increases visceral fat, which increases inflammation, which worsens insulin resistance, which promotes further fat storage.

This is one of the key mechanisms behind the symptoms of low testosterone that many men describe as “feeling like everything is getting worse at once.” The metabolic deterioration is not separate from the body composition changes, the fatigue, and the reduced motivation. They are all downstream of the same hormonal deficit.

Reduced Skeletal Muscle Mass and GLUT4 Expression

Skeletal muscle is responsible for approximately 80 percent of insulin-mediated glucose disposal in the postprandial state. Testosterone is a primary driver of skeletal muscle protein synthesis and muscle fibre maintenance. When testosterone declines, muscle mass decreases, and with it the body’s total capacity for glucose clearance. Additionally, testosterone directly influences the expression of GLUT4 glucose transporters on muscle cell membranes. GLUT4 is the protein that translocates to the cell surface in response to insulin binding, creating the physical channel through which glucose enters the cell. Lower testosterone means fewer GLUT4 transporters, which means less efficient glucose uptake per unit of insulin.

This pathway explains why resistance training, which increases both muscle mass and GLUT4 density, is one of the most effective interventions for insulin resistance. It also explains why testosterone cypionate combined with resistance training produces larger improvements in insulin sensitivity than either intervention alone, a synergy that has direct relevance for both TRT patients and performance users.

Hepatic Insulin Resistance

The liver plays a central role in glucose homeostasis through glycogen storage and gluconeogenesis. Low testosterone is associated with increased hepatic fat accumulation (non-alcoholic fatty liver disease, which is strongly correlated with hepatic insulin resistance). When the liver becomes insulin-resistant, it fails to suppress gluconeogenesis appropriately, resulting in elevated fasting glucose even when peripheral tissues remain relatively insulin-sensitive. This hepatic component is one reason why fasting glucose alone is an incomplete marker of metabolic health on cycle.

Does Testosterone Replacement Therapy Improve Insulin Sensitivity?

The evidence here is robust and consistent. Multiple randomised controlled trials have demonstrated that testosterone replacement therapy in hypogonadal men produces clinically meaningful improvements in insulin sensitivity.

Kapoor and colleagues conducted a double-blind, placebo-controlled crossover study in hypogonadal men with type 2 diabetes and found that testosterone replacement significantly reduced insulin resistance as measured by HOMA-IR, decreased HbA1c, and reduced waist circumference compared to placebo (Kapoor et al., Eur J Endocrinol, 2006). These effects were evident within three months and were independent of changes in body weight, suggesting that testosterone has direct insulin-sensitising effects beyond its body composition effects.

The TIMES2 trial, a larger multicentre randomised controlled study, confirmed these findings. Jones and colleagues randomised hypogonadal men with type 2 diabetes or metabolic syndrome to testosterone gel or placebo for twelve months. The testosterone group showed significant improvements in insulin resistance, with a 15.2 percent reduction in HOMA-IR compared to placebo, alongside reductions in lipoprotein(a) and improvements in body composition (Jones et al., Diabetes Care, 2011). Notably, the metabolic improvements were progressive over the twelve-month study period, suggesting that the full metabolic benefit of testosterone therapy takes time to manifest.

Grossmann’s comprehensive review of testosterone and type 2 diabetes in men synthesised the available evidence and concluded that the bidirectional relationship between low testosterone and insulin resistance creates a “hypogonadal-obesity-adipocytokine hypothesis” in which hormonal, metabolic, and inflammatory factors reinforce each other (Grossmann, J Clin Endocrinol Metab, 2011). Breaking this cycle with testosterone replacement initiates a cascade of improvements that extends well beyond the direct hormonal effect.

For men already diagnosed with or at risk of diabetes, these findings support the use of testosterone cypionate as an adjunctive metabolic intervention alongside standard diabetes management. For the broader population of men with declining testosterone, they highlight why metabolic blood work should be part of routine monitoring.

What Happens to Insulin Sensitivity at Supraphysiological Testosterone Doses?

This is where the picture becomes more complex and where most content on this topic stops being useful. The TRT literature is clear: restoring testosterone to the physiological range improves insulin sensitivity. But what happens at 300 mg, 500 mg, or 750 mg per week?

Body Composition Continues to Improve

Supraphysiological testosterone doses continue to shift body composition toward lean mass and away from fat mass in a dose-dependent manner. This is well established from the Bhasin dose-response studies. Since body composition is the primary mediator of testosterone’s insulin-sensitising effect, this alone should improve insulin sensitivity. And in lean, actively training men, it often does. Many performance users report stable or improved fasting glucose and insulin levels during a well-managed cycle.

Confounding Factors at High Doses

However, several factors at supraphysiological doses can partially offset the body composition benefit:

Caloric surplus. Most men running performance doses of testosterone cypionate are eating in a deliberate caloric surplus to maximise muscle growth. A sustained caloric surplus, regardless of hormonal status, promotes some degree of insulin resistance through chronic nutrient overload. The testosterone-mediated improvement in nutrient partitioning mitigates this but does not eliminate it entirely. Men on a bulking cycle who gain significant body weight, including some fat, should expect their insulin sensitivity to decline modestly during the surplus phase and recover during the subsequent cutting phase.

Hepatic lipid changes. Supraphysiological androgens alter hepatic lipid metabolism, including reductions in HDL cholesterol and potential increases in LDL cholesterol. These changes, covered in detail in our cholesterol guide, are associated with altered hepatic insulin signalling. The clinical significance during a time-limited cycle is uncertain, but it represents a mechanistic pathway through which high-dose testosterone could blunt its own insulin-sensitising effect at the liver level.

Haematocrit elevation. Testosterone stimulates erythropoiesis, increasing red blood cell mass and haematocrit. Elevated haematocrit increases blood viscosity, which affects microvascular perfusion and can theoretically reduce glucose delivery to peripheral tissues. This is a more speculative mechanism, but it aligns with the observation that polycythaemia is associated with impaired glucose tolerance in some populations. Monitoring haematocrit is important for multiple reasons, including cardiovascular health, and metabolic health adds another rationale.

Oestradiol fluctuation. Oestradiol itself has insulin-sensitising properties. In fact, some of testosterone’s metabolic benefit may be mediated through its aromatisation to oestradiol. Aggressive aromatase inhibitor use that suppresses oestradiol below physiological levels could therefore reduce the insulin-sensitising benefit of testosterone. This is yet another reason to manage oestradiol conservatively, a theme that recurs across oestrogen management, joint health, and now metabolic health.

The Net Effect

For most performance users who train consistently, eat a controlled diet with adequate protein and managed carbohydrate intake, and do not run extreme doses, the net effect of a testosterone cypionate cycle on insulin sensitivity is neutral to mildly positive. The body composition improvements and direct GLUT4 effects outweigh the confounding factors. Problems arise in users who combine high doses with excessive caloric intake, minimal cardiovascular exercise, and aggressive aromatase inhibitor use. In that scenario, insulin sensitivity can meaningfully worsen during the cycle.

How to Monitor Insulin Sensitivity on Testosterone Cypionate

Standard blood work panels for steroid users focus on hormones, haematology, and liver enzymes. Metabolic markers are often overlooked. The following table outlines what to test and how to interpret the results.

Marker Optimal Range on Cycle What It Tells You When to Test
Fasting glucose 4.0 to 5.5 mmol/L (72 to 99 mg/dL) Snapshot of current glucose regulation. Can be normal even with significant insulin resistance if pancreatic compensation is adequate. Every blood draw (fasted 10 to 12 hours)
Fasting insulin Under 10 mIU/L (ideally under 7) High fasting insulin with normal glucose indicates early insulin resistance. The pancreas is working harder to maintain glucose control. Baseline, mid-cycle, end of cycle
HOMA-IR Under 1.5 (calculated: fasting insulin x fasting glucose / 22.5) The gold standard surrogate marker for insulin resistance in clinical research. Values above 2.0 indicate clinically significant insulin resistance. Calculated from fasting glucose and insulin
HbA1c Under 37 mmol/mol (5.5%) Reflects average blood glucose over the preceding 8 to 12 weeks. Provides a longer-term view that smooths out daily fluctuations. Note: elevated haematocrit on cycle can falsely affect HbA1c readings. Baseline, end of cycle
Triglycerides Under 1.7 mmol/L (150 mg/dL) Elevated triglycerides are a hallmark of insulin resistance and metabolic syndrome. Often the first lipid marker to deteriorate. Every blood draw (fasted)
HDL cholesterol Above 1.0 mmol/L (40 mg/dL) Low HDL is both a marker of and contributor to insulin resistance. Supraphysiological androgens commonly suppress HDL. Every blood draw

A critical note on HbA1c interpretation: testosterone cypionate increases erythropoiesis, which means red blood cells are turning over faster. Since HbA1c measures glycated haemoglobin on red blood cells, accelerated red cell turnover can produce a falsely low HbA1c reading because cells do not circulate long enough to accumulate proportional glycation. If your haematocrit is significantly elevated, fasting glucose and HOMA-IR are more reliable metabolic markers than HbA1c.

How to Maximise Insulin Sensitivity on a Testosterone Cypionate Cycle

The following strategies are evidence-based approaches to maintaining or improving insulin sensitivity during a testosterone cypionate cycle. They apply at both TRT and supraphysiological doses.

Resistance Training with Adequate Volume

Resistance training is the single most powerful insulin-sensitising intervention available. Each training session increases GLUT4 translocation and glycogen storage capacity in the worked muscles. The effect is both acute (lasting 24 to 48 hours post-session) and chronic (progressive increase in total muscle mass and GLUT4 density). On a testosterone cypionate cycle, where recovery capacity is enhanced, training four to six days per week with sufficient volume to stimulate each major muscle group twice weekly maximises this effect.

Cardiovascular Exercise

Moderate-intensity cardiovascular exercise (brisk walking, cycling, swimming at 60 to 70 percent of maximum heart rate) for 150 minutes per week improves insulin sensitivity through pathways that are additive to resistance training. Specifically, cardio improves hepatic insulin sensitivity and increases mitochondrial density in muscle tissue, both of which enhance glucose disposal. For men concerned about cardiovascular health on cycle, this volume of cardio provides both metabolic and cardiac protection.

Dietary Strategies

The interaction between diet and insulin sensitivity on cycle deserves detailed attention.

Protein intake. Higher protein diets (2.0 to 2.5 g per kg body weight) support muscle protein synthesis while producing a lower insulin response per calorie compared to carbohydrate. Protein also has a higher thermic effect, meaning more of the ingested energy is dissipated as heat rather than stored.

Carbohydrate timing. Concentrating the majority of carbohydrate intake in the peri-workout window (within two hours before and after training) takes advantage of the period when muscle GLUT4 translocation is highest and insulin sensitivity is most favourable. This is sometimes called “carbohydrate partitioning” and is one of the simplest strategies to improve nutrient utilisation on cycle.

Fibre intake. Dietary fibre, particularly soluble fibre from sources like oats, beans, lentils, and vegetables, slows gastric emptying and reduces the glycaemic impact of meals. A minimum of 30 g of fibre daily is associated with improved insulin sensitivity independent of total caloric intake. Most men on high-calorie bulking diets fall well below this threshold, which contributes to the insulin resistance commonly seen during extended surplus phases.

Minimise refined carbohydrates outside the training window. White bread, sugary cereals, confectionery, and sugary drinks produce rapid glucose spikes that demand large insulin responses. Over time, this chronic insulin demand contributes to receptor downregulation and progressive insulin resistance. This does not mean carbohydrates are inherently problematic. It means the type and timing of carbohydrates matter significantly for metabolic health on cycle.

Sleep

Even a single week of restricted sleep (five hours per night) has been shown to reduce insulin sensitivity by 25 to 30 percent in healthy young men. This effect is mediated through increased cortisol, elevated sympathetic nervous system activity, and altered adipokine signalling. Given that some testosterone cypionate users experience sleep disruption, particularly at higher doses or when oestradiol is poorly managed, prioritising sleep hygiene is a metabolic health intervention as much as a recovery one. Seven to nine hours per night is the evidence-based target.

Limit Alcohol

Alcohol acutely impairs hepatic glucose regulation and chronically promotes hepatic fat accumulation when consumed regularly. Even moderate alcohol intake (two to three drinks, three to four times per week) has been associated with measurable increases in hepatic insulin resistance. For men on cycle who are optimising for metabolic health, limiting alcohol is one of the highest-impact dietary modifications available.

Does Testosterone Cypionate and Insulin Sensitivity Interact with Semaglutide?

This is an increasingly relevant question as GLP-1 receptor agonists like semaglutide become more widely used in the bodybuilding and performance enhancement community. Semaglutide is a potent insulin sensitiser that works through multiple mechanisms: it enhances insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and promotes satiety, leading to reduced caloric intake and weight loss.

The combination of testosterone cypionate and semaglutide is pharmacologically logical for men who are insulin-resistant or carrying excess body fat. Testosterone addresses the hormonal and body composition components of insulin resistance, while semaglutide addresses the appetite regulation and incretin pathways. There are no known direct pharmacological interactions between the two compounds.

However, users should be aware that semaglutide’s appetite-suppressing effect can make it difficult to consume enough calories and protein to support muscle growth on a testosterone cypionate bulking cycle. This combination is better suited to recomposition or cutting phases where the goal is simultaneous fat loss and lean mass preservation. Our cutting cycle guide covers dietary frameworks that align with this objective.

Testosterone Cypionate and Metabolic Syndrome: Breaking the Cycle

Metabolic syndrome is defined by the co-occurrence of at least three of the following five criteria: elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose. It represents a clustering of cardiovascular and metabolic risk factors that dramatically increases the risk of heart disease, stroke, and type 2 diabetes.

The prevalence of metabolic syndrome increases with age and correlates inversely with testosterone levels. A comprehensive review by Corona and colleagues examined the evidence linking testosterone to metabolic syndrome components and concluded that testosterone deficiency should be considered both a consequence and a cause of metabolic syndrome, creating a vicious cycle that can be broken by testosterone restoration (Corona et al., J Endocrinol Invest, 2011).

For men over 40 presenting with symptoms of low testosterone alongside two or more metabolic syndrome criteria, the case for testosterone assessment and potential replacement is strong from a purely metabolic standpoint. Testosterone cypionate at TRT doses of 100 to 200 mg per week, combined with lifestyle modifications, addresses the hormonal root of the metabolic dysfunction while the dietary and exercise changes address the behavioural components. The two interventions are synergistic, not redundant.

Common Myths About Testosterone and Blood Sugar

Several misconceptions circulate in the steroid-using community about testosterone and metabolic health. These deserve direct correction.

Myth: “Testosterone causes diabetes.” This is the opposite of what the evidence shows. Low testosterone is associated with increased diabetes risk. Restoring testosterone improves metabolic health. Supraphysiological doses do not cause diabetes in otherwise healthy men, although the dietary excesses that often accompany bulking cycles can promote insulin resistance independent of the testosterone itself.

Myth: “You need to take metformin on cycle.” Metformin is a pharmaceutical insulin sensitiser that has gained popularity in bodybuilding circles. While metformin does improve insulin sensitivity, it also activates AMPK, which can interfere with the mTOR signalling pathway that drives muscle protein synthesis. For most testosterone cypionate users who are not clinically insulin-resistant, the dietary and exercise strategies described above are more appropriate and do not carry the potential trade-off of blunted muscle growth. Metformin has a legitimate role for users with documented insulin resistance (HOMA-IR above 2.5), but it should not be a default addition to every cycle.

Myth: “Insulin sensitivity doesn’t matter if you’re lean.” Lean individuals can be insulin-resistant, a phenomenon sometimes called “metabolically obese, normal weight.” This is driven by hepatic fat accumulation, poor diet quality, inadequate physical activity, or genetic predisposition. Being lean on cycle does not guarantee metabolic health, particularly if the leanness is maintained through caloric restriction without attention to macronutrient quality.

Myth: “HGH always improves insulin sensitivity on a Test Cyp cycle.” This is actually backwards. Growth hormone at supraphysiological doses is diabetogenic. It promotes hepatic glucose output and reduces peripheral glucose uptake. Users who combine testosterone cypionate with HGH should be particularly vigilant about monitoring fasting glucose and HOMA-IR, as the metabolic effects of the two compounds can work in opposing directions.

The Long-Term Metabolic Picture

For men using testosterone cypionate as part of long-term TRT, the metabolic trajectory is generally positive. Multiple studies with follow-up periods of five to ten years show progressive improvements in metabolic syndrome markers, including sustained reductions in waist circumference, triglycerides, and fasting glucose. These improvements are maintained as long as testosterone therapy continues and are accompanied by the cardiovascular and cardiac benefits associated with improved metabolic health.

For men using testosterone cypionate in discrete performance cycles, the metabolic picture depends heavily on what happens between cycles. The body composition gains achieved on cycle, if maintained during the off-period through continued training and appropriate nutrition, provide lasting insulin-sensitising benefits. Conversely, men who regain significant fat between cycles negate these benefits and may progressively worsen their metabolic baseline.

This is one of the strongest arguments for a measured, sustainable approach to cycling. A well-planned cycle length followed by effective recovery and maintained training produces better long-term metabolic outcomes than aggressive cycles followed by rebound weight gain. The realistic results of a well-managed cycle include metabolic improvement as a genuine, measurable outcome, not just a mirror-visible change.

Frequently Asked Questions

Does testosterone cypionate and insulin sensitivity improve at TRT doses?

Yes. The evidence is consistent that restoring testosterone to the physiological range (typically 100 to 200 mg of testosterone cypionate per week) improves insulin sensitivity as measured by HOMA-IR, reduces fasting glucose, and lowers HbA1c in hypogonadal men. The improvement develops progressively over three to twelve months and is maintained with continued therapy.

Should I take metformin on a testosterone cypionate cycle?

Only if you have documented insulin resistance (HOMA-IR above 2.5) or pre-diabetes confirmed by blood work. For metabolically healthy men, metformin’s potential interference with muscle protein synthesis via AMPK activation makes it an unfavourable trade-off. Dietary management, resistance training, and cardiovascular exercise are more appropriate first-line insulin-sensitising strategies on cycle.

Can testosterone cypionate and insulin sensitivity monitoring replace standard diabetes screening?

No. While monitoring fasting glucose and HOMA-IR on cycle provides useful metabolic data, it does not replace formal diabetes screening through your GP, which may include an oral glucose tolerance test. Men with risk factors for type 2 diabetes should undergo standard screening regardless of testosterone status.

Does high-dose testosterone cypionate cause insulin resistance?

High-dose testosterone cypionate itself does not directly cause insulin resistance. However, the caloric surplus typically adopted during bulking, combined with potential hepatic lipid changes and reduced cardiovascular exercise, can promote insulin resistance during a high-dose cycle. The testosterone’s body composition effects partially offset this, but dietary management remains essential.

How does oestradiol relate to testosterone cypionate and insulin sensitivity?

Oestradiol has independent insulin-sensitising effects. Some of testosterone’s metabolic benefit is mediated through aromatisation to oestradiol. Aggressively suppressing oestradiol with aromatase inhibitors may therefore reduce the insulin-sensitising effect of testosterone cypionate. Maintaining oestradiol in the 20 to 40 pg/mL range, as recommended in our oestrogen management guide, supports both joint health and metabolic health.

References

  1. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):5462-5468. PubMed 16670166
  2. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. PubMed 15956998
  3. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 randomised controlled study). Diabetes Care. 2011;34(4):828-837. PubMed 21849636
  4. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341-2353. PubMed 20173018
  5. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Endocrinol Invest. 2011;34(7):557-567. PubMed 21592162

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Anabolic steroid use carries health risks. Consult a qualified healthcare professional before beginning any testosterone cypionate protocol. Hemi Pharma Testosterone Cypionate 200mg is independently verified by Janoshik Analytical, with every vial authenticated via QR code. Read 200+ verified reviews from UK customers.

Shopping Basket
Scroll to Top